Elsevier

Transplantation Proceedings

Volume 37, Issue 1, January–February 2005, Pages 345-347
Transplantation Proceedings

Ischemia-reperfusion injury
Kidney
Delayed graft function: Risk factors, consequences and parameters affecting outcome—results from MOST, A Multinational Observational Study

https://doi.org/10.1016/j.transproceed.2004.12.297Get rights and content

Abstract

Background

Delayed graft function (DGF) is a common complication after renal transplantation, and may affect graft function. The aim of this analysis was to evaluate risk factors for DGF, as well as parameters and events influencing graft function after DGF. We analyzed data collected in an ongoing international, prospective; observational study, the Neoral-MOST (Multinational Observational Study in renal Transplantation), and included in the analysis all patients with cadaveric kidney transplants for whom renal function at 1 year posttransplantation was documented (N = 8950). Logistic regression was used to evaluate the risk factors for DGF occurrence, and multifactorial analysis of variance (ANCOVA) to assess the relevance of different factors for GFR at 1 year.

Results

Higher donor age, longer CIT, male recipients, Caucasian recipients, high recipients body mass index, and PRA were all associated with a higher risk for DGF. Renal function of former DGF kidneys at 1 year was lower in kidneys of elder donors, or which had experienced rejection or CMV infection. Variations of the maintenance regimen at 1 year posttransplantation were not associated with better graft function. Multifactorial analysis showed donor age and acute rejection as significant independent factors.

Conclusions

Most factors increasing the risk for DGF or having a negative impact on renal function at 1 year in grafts with DGF are predetermined. Additional posttransplant damage by acute rejection was associated with further reductions in GFR. Preventing acute rejection is an important step in achieving optimal function of DGF grafts.

Section snippets

Study design

The Neoral-MOST study is an international, prospective, observational ongoing study set up to investigate the use and impact of different immunosuppressive regimens in combination with Neoral (cyclosporine microemulsion, Novartis, Basel) on clinical outcomes after solid organ transplantation. It involves 185 transplant units (155 renal, 26 liver, 4 both) from 38 countries located in Europe, Asia-Pacific, Latin America, Canada, and Australia. To qualify for enrolment, patients need to have

Results

At the time of analysis, 8950 patients who had received a cadaveric graft provided sufficient information to contribute to the analyses on 1-year GFR. Among these, 2028 (22.7%) had DGF and 6922, IGF.

Discussion

This analysis of a global transplant population confirmed donor age and CIT as highly significant risk factors for DGF, as published recently by Irish et al based on US data.2 In addition, recipient obesity had a significant influence on DGF incidence. In our global, non-US data set with very few black recipients, Caucasian race was a risk factor and was associated with a higher DGF incidence compared to the other races (mainly oriental), even when we corrected for regions. Not unexpectedly,

Acknowledgments

The data have been collected by 159 renal transplantation centers participating in the Neoral®-MOST Study. The statistical analyses were performed by Oxford Pharmaceutical Sciences, UK.

References (7)

There are more references available in the full text version of this article.

Cited by (47)

  • Predictive Factors for Improved Renal Function in Renal Transplantation Recipients

    2020, Transplantation Proceedings
    Citation Excerpt :

    Meanwhile, arteries were categorized into single and multiple artery. The kidney side for the donors was grouped into left and right, and the DGF was divided into yes and no based on the presence of delay [17,18]. We used the statistical software SPSS version 16.0 (IBM Corp, Armonk, NY, United States) to perform χ2 testing on each parameter for bivariate analysis.

View all citing articles on Scopus

Sponsored by Novartis Pharma AG, Basel, Switzerland

View full text